Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Niaodukang (NDK) is a traditional Chinese herbal formula (mixture) primarily used for the treatment of chronic kidney disease (CKD) and its associated complications, including chronic kidney disease-mineral and bone disorder (CKD-MBD) and intestinal barrier dysfunction. The preparation is composed of five botanical ingredients: *Rheum officinale*, *Salvia miltiorrhiza*, *Astragalus membranaceus* (or *Astragalus aaronii*), *Carthamus tinctorius*, and *Sanguisorba officinalis*. NDK functions by reducing serum creatinine and blood urea nitrogen levels, suppressing systemic micro-inflammation, and restoring the integrity of the intestinal epithelial barrier. Its molecular mechanism involves the modulation of the miR-146a/NF-κB signaling pathway and the inhibition of the TRAF3/NF-κB2 pathway. Formononetin, a flavonoid derived from *Astragalus*, has been identified as a principal bioactive compound contributing to its therapeutic effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Niaodukang.